0001824293-24-000007.txt : 20240108 0001824293-24-000007.hdr.sgml : 20240108 20240105190511 ACCESSION NUMBER: 0001824293-24-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GRI BIO, Inc. CENTRAL INDEX KEY: 0001824293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824369909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40034 FILM NUMBER: 24517948 BUSINESS ADDRESS: STREET 1: 2223 AVENIDA DE LA PLAYA STREET 2: SUITE 208 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (619) 400-1171 MAIL ADDRESS: STREET 1: 2223 AVENIDA DE LA PLAYA STREET 2: SUITE 208 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Vallon Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20200910 8-K 1 val-20240105.htm 8-K val-20240105
FALSE000182429300018242932024-01-052024-01-05

Image_0.jpg

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2024
Image_8.jpg
GRI BIO, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4003482-4369909
(State or other jurisdiction(Commission File Number)(IRS Employer Identification No.)
of incorporation)
2223 Avenida de la Playa, #208
La Jolla, CA 92037
(Address of principal executive offices and zip code)
(619) 400-1170
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Image_8.jpg
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
GRI
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Image_0.jpg

Image_8.jpg


Item 3.01     Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On January 5, 2024, GRI Bio, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), indicating that the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Letter is in addition to the previously disclosed letter received on November 22, 2023 from the Staff notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and annual net income of less than $500,000 maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). Neither the Letter nor Notice has an immediate effect on the Company’s continued listing on The Nasdaq Capital Market.
Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180-calendar day period, or until July 3, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. The Minimum Bid Price Requirement will be met if the Company’s common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar day period, unless Nasdaq exercises its discretion to extend such 10‑day period. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180-calendar day period, subject to satisfying the conditions in the applicable Nasdaq Listing Rules. If, before the Compliance Date, the Company’s common stock has a closing bid price of $0.10 per share or less for ten consecutive trading days, the Staff will issue a Staff Delisting Determination under Nasdaq Listing Rule 5810 with respect to the Company’s common stock.
The Company was also provided 45 calendar days, or until January 6, 2024, to submit a plan to regain compliance with the Stockholders’ Equity Requirement (the “Compliance Plan”). If the Compliance Plan is determined to be acceptable to the Staff, the Staff would have the discretion to grant the Company an extension of 180-calendar days from the date of the Notice to regain compliance with the Stockholders’ Equity Requirement.
There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Compliance Plan will be accepted or that, if it is, the Company will be able to regain compliance. If the Staff does not accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected and that the Company’s common stock is subject to delisting. At that time, the Company may appeal the Staff’s determination to a Nasdaq Hearing Panel. The Company is monitoring the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement, including holding the previously disclosed special meeting of stockholders to be held on January 19, 2024 (the “Special Meeting”) to vote on the proposed reverse stock split of the Company’s common stock.
Safe Harbor for Forward-Looking Statements
Certain statements contained in this communication may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “predicts,” “plans,” “expects,” “anticipates,” “believes,” “goal,” “target,” “estimate,” “potential,” “may,” “might,” “could,” “see,” “seek,” “forecast” and similar words. Forward-looking statements are based on the Company’s current plans and expectations and involve risks and uncertainties which are, in many instances, beyond the Company’s control, and which could cause actual results to differ materially from those included in or contemplated or implied by the forward-looking statements. Such risks and uncertainties include, among others, the Company’s ability to regain or maintain compliance with Nasdaq’s continued listing requirements, timely file it's Compliance Plan in accordance with Nasdaq rules and submit a Compliance Plan that is acceptable to the Staff, the potential delisting of the Company’s common stock from The Nasdaq Capital Market due to its failure to comply with the Stockholders’ Equity Requirement or the Minimum Bid Price Requirement, the ability of the Company to regain compliance with the Minimum Bid Price Requirement by performing a reverse stock split, and other risks, uncertainties and factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and subsequent filings with the SEC. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this communication as of this date and assumes no obligations to update the information included in this communication or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Participants in the Solicitation
The Company and its directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the Special Meeting. Investors and shareholders may obtain more detailed information regarding the names, affiliations and interests of the Company’s directors and officers


in the definitive proxy statement with respect to the Special Meeting filed by the Company with the SEC on January 2, 2024 (the “Definitive Proxy”), which may be obtained free of charge from the sources indicated below.
Additional Information and Where to Find It
The Company urges investors, shareholders and other interested persons to read the Definitive Proxy as well as other documents filed by the Company with the SEC, because these documents will contain important information about the Company and the Special Meeting. Shareholders may obtain copies of the Definitive Proxy and such other documents, without charge, at the SEC’s website at www.sec.gov.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 5, 2024GRI BIO, INC.
By:/s/ Leanne Kelly
Name:Leanne Kelly
TitleChief Financial Officer



 EX-101.SCH 2 val-20240105.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 val-20240105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 4 val-20240105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 5 val-20240105_g1.jpg GRAPHIC begin 644 val-20240105_g1.jpg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val-20240105_g2.jpg GRAPHIC begin 644 val-20240105_g2.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 05, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 05, 2024
Entity Registrant Name GRI BIO, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40034
Entity Tax Identification Number 82-4369909
Entity Address, Address Line One 2223 Avenida de la Playa
Entity Address, Address Line Two #208
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 619
Local Phone Number 400-1170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol GRI
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001824293
Amendment Flag false
XML 8 val-20240105_htm.xml IDEA: XBRL DOCUMENT 0001824293 2024-01-05 2024-01-05 false 0001824293 8-K 2024-01-05 GRI BIO, INC. DE 001-40034 82-4369909 2223 Avenida de la Playa #208 La Jolla CA 92037 619 400-1170 false false false false Common Stock, par value $0.0001 per share GRI true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://wwwvallon-pharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports val-20240105.htm val-20240105.xsd val-20240105_lab.xml val-20240105_pre.xml val-20240105_g1.jpg val-20240105_g2.jpg http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "val-20240105.htm": { "nsprefix": "val", "nsuri": "http://wwwvallon-pharma.com/20240105", "dts": { "inline": { "local": [ "val-20240105.htm" ] }, "schema": { "local": [ "val-20240105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "val-20240105_lab.xml" ] }, "presentationLink": { "local": [ "val-20240105_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://wwwvallon-pharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "val-20240105.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "val-20240105.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://wwwvallon-pharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001824293-24-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001824293-24-000007-xbrl.zip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